Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 2/20 | 0.49 |
| ▸ | PRCP | P42785 | 7/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.43 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | HPGDS | O60760 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30643533 | 1.00 | NR1I2 (0.49) | NR1I2PRCPCYP3A4CYP2C9ABCB11 | |
| SCHEMBL15372079 | 0.90 | NR1I2 (0.47) | NR1I2PRCPCYP3A4CYP2C9ABCB11 | |
| SCHEMBL10213444 | 0.90 | NR1I2 (0.47) | NR1I2PRCPCYP3A4CYP2C9ABCB11 | |
| SCHEMBL10170870 | 0.90 | NR1I2 (0.47) | NR1I2PRCPCYP3A4CYP2C9ABCB11 | |
| SCHEMBL2709583 | 0.89 | PRCP (0.50) | NR1I2PRCPCYP3A4CYP2C9ABCB11 | |
| SCHEMBL18462513 | 0.89 | PRCP (0.50) | NR1I2PRCPCYP3A4CYP2C9ABCB11 | |
| SCHEMBL204446 | 0.89 | PRCP (0.50) | NR1I2PRCPCYP3A4CYP2C9ABCB11 | |
| SCHEMBL20952483 | 0.89 | NR1I2 (0.49) | NR1I2PRCPCYP3A4CYP2C9ABCB11 | |
| SCHEMBL19513739 | 0.88 | NR1I2 (0.45) | NR1I2PRCPCYP3A4CYP2C9ABCB11 | |
| SCHEMBL17327262 | 0.88 | PRCP (0.51) | NR1I2PRCPCYP3A4CYP2C9ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017181383-A1 | HEPATITIS C VIRUS INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-10-26 | — | — | WO | claimed |
| EP-3445367-B1 | HEPATITIS C VIRUS INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-11-22 | — | — | EP | disclosed |
| US-10787441-B2 | Hepatitis C virus inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20190127355-A1 | HEPATITIS C VIRUS INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-05-02 | — | — | US | disclosed |
| WO-2017181383-A1 | HEPATITIS C VIRUS INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-10-26 | — | — | WO | disclosed |
| WO-2017184476-A1 | HEPATITIS C VIRUS INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787441-B2 | Hepatitis C virus inhibitors | HAVCR2, FABP1, SLC10A1 | NR1I2 110/4885PRCP 313/4885CYP3A4 140/4885 |
| US-20190127355-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, FABP1, SLC10A1 | NR1I2 110/4885PRCP 313/4885CYP3A4 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.